Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

179.25 -2.82 (-1.55%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 Next >

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 19, 2022

Via Benzinga

Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate ↗

August 19, 2022

The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of...

Via Benzinga

Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help ↗

August 11, 2022

Today's depression drugs don't fit many patients' needs. Biotech companies may change that.

Via Investor's Business Daily

What 4 Analyst Ratings Have To Say About Axsome Therapeutics ↗

August 10, 2022

Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings within the last quarter:

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Axsome Therapeutics: Q2 Earnings Insights ↗

August 09, 2022

Axsome Therapeutics (NASDAQ:AXSM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Ratings for Axsome Therapeutics ↗

June 29, 2022

Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:

Via Benzinga

7 Small-Cap Growth Stocks With 1,000% Upside Potential ↗

July 31, 2022

Here're 7 small-cap growth stocks with 1,000% upside potential. ACLS, AXSM, GBT, GPRO, HCAT, SKLZ, and VERU can make great investments.

Via InvestorPlace

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

AXSOME THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM

July 30, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 28, 2022

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why ↗

June 27, 2022

The stock surged by double digits in early trading.

Via Investor's Business Daily

7 Biotech Stocks to Buy for Q3 ↗

July 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

Via InvestorPlace

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

July 12, 2022

From The Schall Law Firm

Via Business Wire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)

July 11, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

July 11, 2022

From The Schall Law Firm

Via Business Wire

AXSOME DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm

July 08, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

NASDAQ:AXSM Investor Notice: Deadline on July 12, 2022 in Lawsuit Against Axsome Therapeutics, Inc. ↗

July 08, 2022

San Diego, CA -- (SBWIRE) -- 07/08/2022 -- The Shareholders Foundation announced that a deadline is coming up on July 12, 2022 in the lawsuit filed for certain investors of Axsome Therapeutics, Inc....

Via SBWire

Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names ↗

July 06, 2022

Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.

Via Investor's Business Daily

Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying ↗

July 06, 2022

Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.

Via Investor's Business Daily

ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

July 04, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ROSEN, A LEADING NATIONAL FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

June 29, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder ↗

June 29, 2022

Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea...

Via Benzinga

Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

June 28, 2022

Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...

Via FinancialNewsMedia

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗

June 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗

June 28, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session ↗

June 27, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.

Via Benzinga

EV Stocks TSLA, NIO, RIVN See Price Targets Slashed ↗

June 27, 2022

Electric vehicle (EV) stocks are in the news today after Mizuho analyst Vijay Rakesh weighed in on several companies in the space.

Via InvestorPlace

Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical ↗

June 27, 2022

Axsome Therapeutics Inc (NASDAQ: AXSM) shares rallied 40% on Monday morning after the company received some positive news from the U.S. Food and Drug Administration regarding its AXS-05 novel treatment...

Via Benzinga

Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal ↗

June 27, 2022

Axsome Therapeutics (AXSM) stock is rising higher on Monday following an update from the FDA about product labeling for one of its drugs.

Via InvestorPlace

< Previous 1 2

...

20 21 22 23 24 25 26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.